Filing Flows › Curaleaf Holdings (CURLF) › Guidance & outlook
Curaleaf Holdings (CURLF) guidance and outlook
Curaleaf Holdings' 10-Q filed Nov 3, 2026 makes 9 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 3, 2026
- As the industry matures, we anticipate escalating competition from companies with longer operating histories and/or greater financial resources.
- We will continue to build our brand portfolio through new product innovation and developing brand worlds that serve consumers and patients.
- We will continue to target growth opportunities as existing state programs stabilize or as new state programs launch.
- During 2025, we received the only foreign issued license to operate in Turkey upon commencement of its medical cannabis market, expected in 2027.
- Upon our transition from complying with MJDS requirements as a foreign private issuer to complying with U.S. domestic issuer requirements, we expect to file future shelf registration statements on applicable domestic filer forms.
- Under the NCIB, other than purchases made under block purchase exemptions, we will be allowed, subject to applicable securities laws and stock exchange requirements, to purchase daily, through the facilities of the TSX, a maximum of 70,046 SVS, representing 25% of the average daily trading volume of 280,186 SVS, as calculated per the TSX rules for the six-month period ended on March 31, 2026.
- Under the Amended Offer, each Aurora shareholder whose Aurora Shares are taken up by the Company will be entitled to receive, for each Aurora Share, $1.00 in cash and 0.4013 of a SVS, subject to a maximum value per Share of $6.00.
- There are numerous risks associated with the Amended Offer, and there can be no assurance that the Amended Offer will be successful, or if it is successful, that the Company will be able to acquire the remaining Aurora Shares.
- The critical accounting estimates that we believe affect our more significant judgments and estimates used in the preparation of our Condensed Consolidated Financial Statements presented in this Quarterly Report on Form 10-Q are described under Critical Accounting Policies and Estimates included in the section titled ‘Management's Discussion and Analysis of Financial Condition and Results of Operations’ in Part…
Curaleaf Holdings' latest quarter
Curaleaf Holdings, Q3 2026: revenue $353M (+11% year over year), operating margin 0.8%, net loss $32.7M, operating cash flow $21.1M. The chart follows the revenue to costs, profit and cash.
Questions
What does Curaleaf Holdings expect?
As the industry matures, we anticipate escalating competition from companies with longer operating histories and/or greater financial resources. We will continue to build our brand portfolio through new product innovation and developing brand worlds that serve consumers and patients. We will continue to target growth opportunities as existing state programs stabilize or as new state programs launch.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.